Risk Prediction for Early CKD in Type 2 Diabetes.

ABSTRACT:

Background and objectives

Quantitative data for prediction of incidence and progression of early CKD are scarce in individuals with type 2 diabetes. Therefore, two risk prediction models were developed for incidence and progression of CKD after 5.5 years and the relative effect of predictors were ascertained.

Design, setting, participants, & measurements

Baseline and prospective follow-up data of two randomized clinical trials, ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) and Outcome Reduction with Initial Glargine Intervention (ORIGIN), were used as development and independent validation cohorts, respectively. Individuals aged ≥55 years with type 2 diabetes and normo- or microalbuminuria at baseline were included. Incidence or

SUBMITTER: Dunkler D 

PROVIDER: S-EPMC4527032 | biostudies-literature | 2015 Aug

REPOSITORIES: biostudies-literature